Centinel Spine received an allogeneic bone graft indication for its anterior lumbar product family.
Here are five things to know:
1. The FDA cleared the STALIF MIDLINE, MIDLINE II and MIDLINE II-Ti (Ti-ACTIVE) devices for use with allogeneic bone graft in lumbar spinal fusions.
2. The Centinel Spine standalone devices have a no-profile design and are integrated interbody systems for use with autograft and/or allogeneic bone graft in lumbar and cervical fusion procedures.
3. The STALIF C and STALIF C-Ti received the allogeneic clearance late last year.
4. The MIDLINE II provides the traditional STALIF compressive fixation but also has a horizontal inclination of lag screws.
5. Centinel Spine began operations in August 2008 through the merger/acquisition of Raymedica and Surgicraft.
"In my practice, I prefer to use MIDLINE II for my anterior spinal fusion procedures as it provides the best stability and offers many unique features," said Jon I. White, MD, of Irvine (Calif.) Orthopaedic Associates. "The new allogeneic indication gives me additional peace of mind that I am providing the best care for my patients."
More articles for orthopedic devices:
4 notes on Aurora Spine's new MIS lumbar interbody cage with TiNano
5 key observations in orthobiologics
Invuity begins NASDAQ trading, revises IPO close date